Abstract
The influence of the route of administration and treatment schedule of a yeast immunoadjuvant, Candida albicans (CA) on the degree of success achieved with an immunochemotherapy regimen in a virus-induced murine lymphoma has been evaluated. To this end, histocompatible CD2F1 mice received IP or IV inoculations of LSTRA lymphoma cells and were subjected to various treatments with inactivated CA and bis, 1, chloroethyl nitrosourea (BCNU).
The results showed that CA may significantly increase the antitumor efficiency of BCNU when (a) the tumor is inoculated IP and not IV; (b) CA is administered before (on day −14) and after (on days +1 and/or day +8) LSTRA challenge; (c) CA is given IP as a post-tumor treatment.
To ascertain whether the immunoadjuvant effect was anatomically restricted to the peritoneal cavity (PC), spreading of IP injected lymphoma was studied by means of LSTRA cells labeled with 3–5′iodo-deoxyuridine 125I (125IUdR) and tumor bioassay in spleen, lung, kidney, liver, and PC of recipient mice. The results showed that IP tumor challenge led to early (1 h) generalized neoplasia in both untreated and CA-pretreated hosts.
Therefore, the combined antitumor effects of chemotherapy and CA are not restricted to the PC but rather the result of systemic immunity. In conclusion, in our system the PC seems to be a preferential site for eliciting generalized antilymphoma host responses markedly amplified by selected schedules of immunoadjuvant administration.
Keywords: Peritoneal Cavity, Candida Albicans, BCNU, Chloroethyl, Recipient Mouse
References
- 1.Bistoni F, Marconi P, Pitzurra M, Frati L, Spreafico F, Goldin A, Bonmassar E. Combined effects of BCG or Candida albicans (CA) with antitumor agents against a virus-induced lymphoma in mice. Eur J Cancer. 1979;15:1305. doi: 10.1016/0014-2964(79)90106-3. [DOI] [PubMed] [Google Scholar]
- 2.Bonmassar E, Cudkowitz G, Vadlamudi S, Goldin A. Influence of tumor-host differences at a single hystocompatibility locus (H-1) on the antileukemia effect of 1,3-bis-(2-chloroethyl)-1-nitrosourea (NSC 409962) Cancer Res. 1970;30:2538. [PubMed] [Google Scholar]
- 3.Cassone A, Marconi P, Bistoni F, Mattia E, Sbaraglia G, Garaci E, Bonmassar E. Immunoadjuvant effects of Candida albicans and its cell wall fractions in a mouse lymphoma model. Cancer Immunol Immunother. 1981;10:181. [Google Scholar]
- 4.Di Luzio MR, Hoffman NE, Cook JA, Browder W, Mansell PWA. A glucan-induced enhancement in host resistance to experimental tumors. In: Chirigos MA, editor. Control of neoplasia by modulation of immune system, vol 3. New York: Raven Press; 1977. p. 475. [Google Scholar]
- 5.Fisher B, Linta J, Hanlon J, Saffer E. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophospamide. V. Comparison of the effects of tilorone hydrochloride, Levamisole, methanol-soluble fractions of Mycobacterium butyricum, BCG and a non-viable aqueous extract of Brucella abortus preparations in treatment of mice with tumors. J Natl Cancer Inst. 1978;60:391. doi: 10.1093/jnci/60.2.391. [DOI] [PubMed] [Google Scholar]
- 6.Glynn JP, Bianco AR, Goldin A. Studies on induced resistance against isotransplants of virus-induced leukemia. Cancer Res. 1964;24:502. [PubMed] [Google Scholar]
- 7.Herberman RB. Cell-mediated immunity to tumor cells. Adv Cancer Res. 1974;24:502. doi: 10.1016/s0065-230x(08)60055-x. [DOI] [PubMed] [Google Scholar]
- 8.Klein G. Immunological surveillance against neoplasia. Harvey Lect. 1975;69:71. [PubMed] [Google Scholar]
- 9.Lodder J. The yeasts: a taxonomic study. Amsterdam London: North Holland; 1970. p. 914. [Google Scholar]
- 10.Marconi P, Bistoni F, Boncio L, Bersiani A, Bovi P, Pitzurra M. Utilizzazione di soluzione salina ipertonica di cloruro di potassio (KCl 3M) per la estrazione di antigeni solubili da Candida albicans . Ann Sclavo. 1976;18:61. [PubMed] [Google Scholar]
- 11.Mathé G, Halle-Pannenko O, Bourut G. Immune manipulation of BCG administered before or after cyclophosphamide chemoimmunotherapy of L 1210 leukemia. Eur J Cancer. 1974;10:661. doi: 10.1016/0014-2964(74)90005-x. [DOI] [PubMed] [Google Scholar]
- 12.Minden P, McClatchy JK, Wainberg M, Weiss DW. Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells. J Natl Cancer Inst. 1974;53:1325. doi: 10.1093/jnci/53.5.1325. [DOI] [PubMed] [Google Scholar]
- 13.Sone S, Fidler JI. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol. 1980;125:2454. [PubMed] [Google Scholar]
- 14.Spreafico F, Bonmassar E. Some aspects of interaction between cancer, drugs and immunity. In: Sela M, editor. Non-specific immunity in the prevention and treatment of cancer, vol 43. Vaticano: Pontificia Academia Scientiarum Scripta Varia; 1978. p. 407. [Google Scholar]
- 15.Stewart-Tull DES. The immunological activities of bacterial peptidoglycans. Annu Rev Microbiol. 1980;34:311. doi: 10.1146/annurev.mi.34.100180.001523. [DOI] [PubMed] [Google Scholar]
- 16.Weiss DW. Tumor antigenicity and approaches to tumor immunotherapy. Curr Top Microbiol Immunol. 1980;89:1. [PubMed] [Google Scholar]
- 17.Zbar B, Bernstein ID, Bartlett GL, Hanna GM, Rapp HI. Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastasis after intralesional injection of living Mycobacterium bovis . J Natl Cancer Inst. 1972;49:119. [PubMed] [Google Scholar]